CEO Lawrence Blatt (Aligos)
December 7, 2020 11:16 AM EST
Deals

With a po­ten­tial $458M per tar­get pay­day, Ali­gos teams up with Mer­ck hop­ing to re­verse biotech's re­cent NASH mal­adies

Max Gelman

Senior Editor

Just a few months af­ter go­ing pub­lic with a $150 mil­lion IPO, Ali­gos Ther­a­peu­tics $AL­GS is aim­ing to fur­ther cap­i­tal­ize on its mo­men­tum with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times